Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1481296
This article is part of the Research Topic Immunoregulation in Urological Disorders: Novel Targets and Therapies View all articles

Bladder cancer immune-related markers： diagnosis, surveillance, and prognosis

Provisionally accepted
田田 杨 田田 杨 1Wanru Luo Wanru Luo 2*Jie Yu Jie Yu 3Huiping Zhang Huiping Zhang 4Meichun Hu Meichun Hu 5Jun Tian Jun Tian 6*
  • 1 College of Pharmacy, Hubei University of Science and Technology, Xianning, China
  • 2 Hubei University of Science and Technology, Xianning, Hubei, China
  • 3 School of Life Science and Technology, Wuhan Polytechnic University, Wuhan, Hubei Province, China
  • 4 Institute of Reproduction Health Research, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hebei Province, China
  • 5 School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei Province, China
  • 6 National Cancer Center, Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

The final, formatted version of the article will be published soon.

    As an immune-related tumor type, bladder cancer has been attracting much attention in the study of its markers. In recent years, researchers have made rapid progress in the study of immune-related markers for bladder cancer. Studies have shown that immune-related markers play an important role in the diagnosis, prognosis assessment and treatment of bladder cancer. In addition, the detection of immune-related markers can also be used to evaluate the efficacy of immunotherapy and predict the treatment response of patients. Therefore, in depth study of the expression of immune-related markers in bladder cancer and their application in the clinic is of great significance and is expected to provide new breakthroughs for individualised treatment of bladder cancer. Future studies will focus more on how to detect immune-related markers with low cost and high accuracy，as well as develop new immunotherapeutic strategies to bring better therapeutic outcomes to bladder cancer patients.

    Keywords: Bladder cancer, Immune-related markers, Tumor immune microenvironment, diagnosis, Treatment, prognosis

    Received: 15 Aug 2024; Accepted: 17 Oct 2024.

    Copyright: © 2024 杨, Luo, Yu, Zhang, Hu and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Wanru Luo, Hubei University of Science and Technology, Xianning, 050091, Hubei, China
    Jun Tian, National Cancer Center, Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.